6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
(	(	(	(	(	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
pyrexia	JJ	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Novartis	NNP	novartis	novartis	novarti	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
Corporation	NNP	corporation	corporation	corpor	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
669	CD	669	669	669	N	O
-	:	-	-	-	N	O
6682	CD	6682	6682	6682	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Serious	JJ	serious	serious	seriou	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
and	CC	and	and	and	N	O
otherwise	RB	otherwise	otherwise	otherwis	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.3	CD	6.3	6.3	6.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rate	NN	rate	rate	rate	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
979	CD	979	979	979	N	O
patients	NNS	patients	patient	patient	N	O
including	VBG	including	including	includ	N	O
647	CD	647	647	647	N	O
adults	NNS	adults	adult	adult	N	O
(	(	(	(	(	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
332	CD	332	332	332	N	O
children	NNS	children	child	children	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
younger	JJR	younger	younger	younger	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
the	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
regimen	NNS	regimen	regimen	regimen	N	O
,	,	,	,	,	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
was	VBD	was	wa	wa	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
(	(	(	(	(	N	O
366	CD	366	366	366	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
non	$	non	non	non	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trials	NNS	trials	trial	trial	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
613	CD	613	613	613	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	NN	dose	dose	dose	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
malaria	NNS	malaria	malaria	malaria	Y	O
between	IN	between	between	between	N	O
ages	NNS	ages	age	age	N	O
2	CD	2	2	2	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
71	CD	71	71	71	N	O
years	NNS	years	year	year	N	O
:	:	:	:	:	N	O
67%	CD	67%	67%	67%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
332	CD	332	332	332	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
younger	JJR	younger	younger	younger	N	O
and	CC	and	and	and	N	O
33%	CD	33%	33%	33%	N	O
(	(	(	(	(	N	O
647	CD	647	647	647	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
.	.	.	.	.	N	O

Males	NNS	males	male	male	N	O
represented	VBD	represented	represented	repres	N	O
73%	CD	73%	73%	73%	N	O
and	CC	and	and	and	N	O
53%	CD	53%	53%	53%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
adult	NN	adult	adult	adult	N	O
and	CC	and	and	and	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
populations	NNS	populations	population	popul	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
enrolled	VBN	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
Thailand	NNP	thailand	thailand	thailand	N	O
,	,	,	,	,	N	O
while	IN	while	while	while	N	O
the	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
enrolled	VBN	enrolled	enrolled	enrol	N	O
in	IN	in	in	in	N	O
Africa	NNP	africa	africa	africa	N	O
.	.	.	.	.	N	O

Tables	NNS	tables	table	tabl	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
show	VBP	show	show	show	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
and	CC	and	and	and	N	O
children	NNS	children	child	children	N	O
respectively	RB	respectively	respectively	respect	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
the	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
collected	VBN	collected	collected	collect	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
but	CC	but	but	but	N	O
only	RB	only	only	onli	N	O
treatment	NN	treatment	treatment	treatment	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
events	NNS	events	event	event	N	O
that	WDT	that	that	that	N	O
appeared	VBD	appeared	appeared	appear	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
below	IN	below	below	below	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequently	RB	frequently	frequently	frequent	N	O
reported	VBD	reported	reported	report	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
pyrexia	RB	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
mild	JJ	mild	mild	mild	N	O
,	,	,	,	,	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
study	NN	study	study	studi	N	O
medication	NN	medication	medication	medic	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
resolved	VBD	resolved	resolved	resolv	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
limited	JJ	limited	limited	limit	N	O
comparative	JJ	comparative	comparative	compar	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
profile	NN	profile	profile	profil	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
appeared	VBD	appeared	appeared	appear	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
antimalarial	JJ	antimalarial	antimalarial	antimalari	N	O
regimen	NN	regimen	regimen	regimen	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
regimen	NNS	regimen	regimen	regimen	N	O
overall	JJ	overall	overall	overal	N	O
:	:	:	:	:	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
647	CD	647	647	647	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
and	CC	and	and	and	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
332	CD	332	332	332	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
children	NNS	children	child	children	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
Adult	NNP	adult	adult	adult	N	O
Patients	NNP	patients	patient	patient	N	O
Treated	NNP	treated	treated	treat	N	O
in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Adults	NNP	adults	adult	adult	N	O
N	NNP	n	n	n	N	O
647	CD	647	647	647	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Headache	VBP	headache	headache	headach	Y	B-AdverseReaction
360	CD	360	360	360	N	O
(	(	(	(	(	N	O
56	CD	56	56	56	N	O
)	)	)	)	)	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
253	CD	253	253	253	N	O
(	(	(	(	(	N	O
39	CD	39	39	39	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
Anorexia	VBP	anorexia	anorexia	anorexia	Y	B-AdverseReaction
260	CD	260	260	260	N	O
(	(	(	(	(	N	O
40	CD	40	40	40	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
Asthenia	VBP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
243	CD	243	243	243	N	O
(	(	(	(	(	N	O
38	CD	38	38	38	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
159	CD	159	159	159	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
147	CD	147	147	147	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
)	)	)	)	)	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
111	CD	111	111	111	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Malaise	RB	malaise	malaise	malais	Y	B-AdverseReaction
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Arthralgia	VBP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
219	CD	219	219	219	N	O
(	(	(	(	(	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
206	CD	206	206	206	N	O
(	(	(	(	(	N	O
32	CD	32	32	32	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Nausea	VBP	nausea	nausea	nausea	Y	B-AdverseReaction
169	CD	169	169	169	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
113	CD	113	113	113	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
Sleep	NNP	sleep	sleep	sleep	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
144	CD	144	144	144	N	O
(	(	(	(	(	N	O
22	CD	22	22	22	N	O
)	)	)	)	)	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
32	CD	32	32	32	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O
Palpitations	NNS	palpitations	palpitation	palpit	Y	B-AdverseReaction
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
Hepatomegaly	VBP	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Splenomegaly	VBP	splenomegaly	splenomegaly	splenomegali	Y	B-AdverseReaction
57	CD	57	57	57	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

Anemia	$	anemia	anemia	anemia	Y	B-AdverseReaction
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Cough	IN	cough	cough	cough	Y	B-AdverseReaction
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
labyrinth	JJ	labyrinth	labyrinth	labyrinth	N	O
disorders	NNS	disorders	disorder	disord	N	O
Vertigo	VBP	vertigo	vertigo	vertigo	Y	B-AdverseReaction
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
Malaria	NNP	malaria	malaria	malaria	Y	B-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
or	CC	or	or	or	N	O
More	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Patients	NNPS	patients	patient	patient	N	O
Treated	NNP	treated	treated	treat	N	O
in	IN	in	in	in	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
Regimen	NNP	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O

System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
Children	NNP	children	child	children	N	O
N	NNP	n	n	n	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
332	CD	332	332	332	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O
Pyrexia	VBP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
381	CD	381	381	381	N	O
(	(	(	(	(	N	O
29	CD	29	29	29	N	O
)	)	)	)	)	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
72	CD	72	72	72	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
63	CD	63	63	63	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Cough	IN	cough	cough	cough	Y	B-AdverseReaction
302	CD	302	302	302	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
242	CD	242	242	242	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
112	CD	112	112	112	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
100	CD	100	100	100	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
61	CD	61	61	61	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
Plasmodium	NNP	plasmodium	plasmodium	plasmodium	N	B-AdverseReaction
falciparum	NN	falciparum	falciparum	falciparum	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
224	CD	224	224	224	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
51	CD	51	51	51	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
Anorexia	VBP	anorexia	anorexia	anorexia	Y	B-AdverseReaction
175	CD	175	175	175	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Headache	VBP	headache	headache	headach	Y	B-AdverseReaction
168	CD	168	168	168	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
56	CD	56	56	56	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
Splenomegaly	VBP	splenomegaly	splenomegaly	splenomegali	Y	B-AdverseReaction
124	CD	124	124	124	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

Anemia	$	anemia	anemia	anemia	Y	B-AdverseReaction
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
disorders	NNS	disorders	disorder	disord	N	O
Hepatomegaly	VBP	hepatomegaly	hepatomegaly	hepatomegali	Y	B-AdverseReaction
75	CD	75	75	75	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Investigations	NNS	investigations	investigation	investig	N	O
Aspartate	NNP	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
51	CD	51	51	51	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Arthralgia	VBP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
Rash	VBP	rash	rash	rash	Y	B-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Children	NNP	children	child	children	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
patients	NNS	patients	patient	patient	N	O
16	CD	16	16	16	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O

Clinically	RB	clinically	clinically	clinic	N	O

significant	JJ	significant	significant	signific	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
children	NNS	children	child	children	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
6	CD	6	6	6	N	O
-	:	-	-	-	N	O
dose	JJ	dose	dose	dose	N	O
regimen	NNS	regimen	regimen	regimen	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
at	IN	at	at	at	N	O
3%	CD	3%	3%	3%	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
are	VBP	are	are	are	N	O
listed	VBN	listed	listed	list	N	O
below	IN	below	below	below	N	O
:	:	:	:	:	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
lymphatic	JJ	lymphatic	lymphatic	lymphat	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
eosinophilia	NN	eosinophilia	eosinophilia	eosinophilia	Y	B-AdverseReaction

Ear	NN	ear	ear	ear	N	O
and	CC	and	and	and	N	O
labyrinth	JJ	labyrinth	labyrinth	labyrinth	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
tinnitus	NN	tinnitus	tinnitus	tinnitu	Y	B-AdverseReaction

Eye	JJ	eye	eye	eye	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
conjunctivitis	NN	conjunctivitis	conjunctivitis	conjunct	Y	B-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphagia	NN	dysphagia	dysphagia	dysphagia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peptic	JJ	peptic	peptic	peptic	N	B-AdverseReaction
ulcer	NN	ulcer	ulcer	ulcer	Y	I-AdverseReaction

General	JJ	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
gait	NN	gait	gait	gait	N	B-AdverseReaction
disturbance	NN	disturbance	disturbance	disturb	N	I-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
abscess	NN	abscess	abscess	abscess	Y	B-AdverseReaction
,	,	,	,	,	N	O
acrodermatitis	NN	acrodermatitis	acrodermatitis	acrodermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
ear	JJ	ear	ear	ear	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
gastroenteritis	NN	gastroenteritis	gastroenteritis	gastroenter	Y	B-AdverseReaction
,	,	,	,	,	N	O
helminthic	JJ	helminthic	helminthic	helminth	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
hookworm	NN	hookworm	hookworm	hookworm	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
impetigo	NN	impetigo	impetigo	impetigo	Y	B-AdverseReaction
,	,	,	,	,	N	O
influenza	NN	influenza	influenza	influenza	Y	B-AdverseReaction
,	,	,	,	,	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
malaria	NN	malaria	malaria	malaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
oral	JJ	oral	oral	oral	N	B-AdverseReaction
herpes	NNS	herpes	herpes	herp	N	I-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
respiratory	JJ	respiratory	respiratory	respiratori	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	B-AdverseReaction
abscess	NN	abscess	abscess	abscess	Y	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

Investigations	NNS	investigations	investigation	investig	N	O
:	:	:	:	:	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
hematocrit	NN	hematocrit	hematocrit	hematocrit	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
lymphocyte	JJ	lymphocyte	lymphocyte	lymphocyt	N	B-AdverseReaction
morphology	NN	morphology	morphology	morpholog	N	I-AdverseReaction
abnormal	NN	abnormal	abnormal	abnorm	N	I-AdverseReaction
,	,	,	,	,	N	O
platelet	NN	platelet	platelet	platelet	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
platelet	NN	platelet	platelet	platelet	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
white	JJ	white	white	white	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
white	JJ	white	white	white	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cell	NN	cell	cell	cell	N	I-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
ataxia	NN	ataxia	ataxia	ataxia	Y	B-AdverseReaction
,	,	,	,	,	N	O
clonus	NN	clonus	clonus	clonu	Y	B-AdverseReaction
,	,	,	,	,	N	O
fine	JJ	fine	fine	fine	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
delay	NN	delay	delay	delay	N	I-AdverseReaction
,	,	,	,	,	N	O
hyperreflexia	NN	hyperreflexia	hyperreflexia	hyperreflexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypoesthesia	NN	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nystagmus	RB	nystagmus	nystagmus	nystagmu	Y	B-AdverseReaction
,	,	,	,	,	N	O
tremor	NN	tremor	tremor	tremor	Y	B-AdverseReaction

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
agitation	NN	agitation	agitation	agit	Y	B-AdverseReaction
,	,	,	,	,	N	O
mood	NN	mood	mood	mood	N	B-AdverseReaction
swings	NNS	swings	swing	swing	N	I-AdverseReaction

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
asthma	NN	asthma	asthma	asthma	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngo	SYM	pharyngo	pharyngo	pharyngo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
laryngeal	NN	laryngeal	laryngeal	laryng	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction

6.3	CD	6.3	6.3	6.3	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
bullous	JJ	bullous	bullous	bullou	N	B-AdverseReaction
eruption	NN	eruption	eruption	erupt	Y	I-AdverseReaction
)	)	)	)	)	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Avoid	NNP	avoid	avoid	avoid	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
QT	NNP	qt	qt	qt	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
,	,	,	,	,	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
those	DT	those	those	those	N	O
taking	VBG	taking	taking	take	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
12.6	CD	12.6	12.6	12.6	N	O
)	)	)	)	)	N	O

Halofantrine	NNP	halofantrine	halofantrine	halofantrin	N	O
and	CC	and	and	and	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
within	IN	within	within	within	N	O
one	CD	one	one	one	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
each	DT	each	each	each	N	O
other	JJ	other	other	other	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
potential	JJ	potential	potential	potenti	N	O
additive	JJ	additive	additive	addit	N	O
effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O

Antimalarials	NNS	antimalarials	antimalarial	antimalari	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
,	,	,	,	,	N	O
unless	IN	unless	unless	unless	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
other	JJ	other	other	other	N	O
treatment	NN	treatment	treatment	treatment	N	O
option	NN	option	option	option	N	O
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
limited	JJ	limited	limited	limit	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

QT	NNP	qt	qt	qt	N	O
prolonging	VBG	prolonging	prolonging	prolong	N	O
drugs	NNS	drugs	drug	drug	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
quinine	NN	quinine	quinine	quinin	N	O
and	CC	and	and	and	N	O
quinidine	NN	quinidine	quinidine	quinidin	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
following	VBG	following	following	follow	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
7.7	CD	7.7	7.7	7.7	N	O
,	,	,	,	,	N	O
12.3	CD	12.3	12.3	12.3	N	O
)	)	)	)	)	N	O

Substrates	NNS	substrates	substrate	substrat	N	O
,	,	,	,	,	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
inducers	NNS	inducers	inducer	induc	N	O
of	IN	of	of	of	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
with	IN	with	with	with	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
potential	JJ	potential	potential	potenti	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
drug	NN	drug	drug	drug	N	O
or	CC	or	or	or	N	O
additive	JJ	additive	additive	addit	N	O
QT	NNP	qt	qt	qt	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
7.2	CD	7.2	7.2	7.2	N	O
,	,	,	,	,	N	O
7.3	CD	7.3	7.3	7.3	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Prolongation	NN	prolongation	prolongation	prolong	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
Interval	NNP	interval	interval	interv	N	O

Some	DT	some	some	some	N	O
antimalarials	NNS	antimalarials	antimalarial	antimalari	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
halofantrine	NN	halofantrine	halofantrine	halofantrin	N	O
,	,	,	,	,	N	O
quinine	NN	quinine	quinine	quinin	N	O
,	,	,	,	,	N	O
quinidine	NN	quinidine	quinidine	quinidin	N	O
)	)	)	)	)	N	O
including	VBG	including	including	includ	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNS	tablets	tablet	tablet	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
prolongation	NN	prolongation	prolongation	prolong	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
QT	NNP	qt	qt	qt	N	I-AdverseReaction
interval	NN	interval	interval	interv	N	I-AdverseReaction
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
electrocardiogram	NN	electrocardiogram	electrocardiogram	electrocardiogram	Y	O
.	.	.	.	.	N	O

Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
avoided	VBN	avoided	avoided	avoid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O

with	IN	with	with	with	N	O
congenital	JJ	congenital	congenital	congenit	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
long	JJ	long	long	long	N	O
QT	NNP	qt	qt	qt	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
condition	NN	condition	condition	condit	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
interval	NN	interval	interval	interv	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
cardiac	NN	cardiac	cardiac	cardiac	N	O
arrhythmias	NN	arrhythmias	arrhythmia	arrhythmia	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
clinically	RB	clinically	clinically	clinic	N	O
relevant	JJ	relevant	relevant	relev	N	O
bradycardia	NN	bradycardia	bradycardia	bradycardia	Y	O
or	CC	or	or	or	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
disease	NN	disease	disease	diseas	N	O
.	.	.	.	.	N	O

with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
family	NN	family	family	famili	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
congenital	JJ	congenital	congenital	congenit	N	O
prolongation	NN	prolongation	prolongation	prolong	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
or	CC	or	or	or	N	O
sudden	JJ	sudden	sudden	sudden	N	O
death	NN	death	death	death	Y	O
.	.	.	.	.	N	O

with	IN	with	with	with	N	O
known	JJ	known	known	known	N	O
disturbances	NNS	disturbances	disturbance	disturb	N	O
of	IN	of	of	of	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
balance	NN	balance	balance	balanc	N	O
,	,	,	,	,	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
.	.	.	.	.	N	O

receiving	VBG	receiving	receiving	receiv	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
class	NN	class	class	class	N	O
IA	NNP	ia	ia	ia	N	O
(	(	(	(	(	N	O
quinidine	NN	quinidine	quinidine	quinidin	N	O
,	,	,	,	,	N	O
procainamide	NN	procainamide	procainamide	procainamid	N	O
,	,	,	,	,	N	O
disopyramide	NN	disopyramide	disopyramide	disopyramid	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
class	NN	class	class	class	N	O
III	NNP	iii	iii	iii	N	O
(	(	(	(	(	N	O
amiodarone	NN	amiodarone	amiodarone	amiodaron	N	O
,	,	,	,	,	N	O
sotalol	NN	sotalol	sotalol	sotalol	N	O
)	)	)	)	)	N	O
antiarrhythmic	JJ	antiarrhythmic	antiarrhythmic	antiarrhythm	N	O
agents	NNS	agents	agent	agent	N	O
;	:	;	;	;	N	O
antipsychotics	NNS	antipsychotics	antipsychotic	antipsychot	N	O
(	(	(	(	(	N	O
pimozide	NN	pimozide	pimozide	pimozid	N	O
,	,	,	,	,	N	O
ziprasidone	NN	ziprasidone	ziprasidone	ziprasidon	N	O
)	)	)	)	)	N	O
;	:	;	;	;	N	O
antidepressants	NNS	antidepressants	antidepressant	antidepress	N	O
;	:	;	;	;	N	O
certain	JJ	certain	certain	certain	N	O
antibiotics	NNS	antibiotics	antibiotic	antibiot	N	O
(	(	(	(	(	N	O
macrolide	JJ	macrolide	macrolide	macrolid	N	O
antibiotics	NNS	antibiotics	antibiotic	antibiot	N	O
,	,	,	,	,	N	O
fluoroquinolone	NN	fluoroquinolone	fluoroquinolone	fluoroquinolon	N	O
antibiotics	NNS	antibiotics	antibiotic	antibiot	N	O
,	,	,	,	,	N	O
imidazole	NN	imidazole	imidazole	imidazol	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
triazole	JJ	triazole	triazole	triazol	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
agents	NNS	agents	agent	agent	N	O
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.6	CD	12.6	12.6	12.6	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

receiving	VBG	receiving	receiving	receiv	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
metabolized	VBN	metabolized	metabolized	metabol	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
cytochrome	NN	cytochrome	cytochrome	cytochrom	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
CYP2D6	NNP	cyp2d6	cyp2d6	cyp2d6	N	O
which	WDT	which	which	which	N	O
also	RB	also	also	also	N	O
have	VBP	have	have	have	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
effects	NNS	effects	effect	effect	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
flecainide	RB	flecainide	flecainide	flecainid	N	O
,	,	,	,	,	N	O
imipramine	NN	imipramine	imipramine	imipramin	N	O
,	,	,	,	,	N	O
amitriptyline	NN	amitriptyline	amitriptyline	amitriptylin	N	O
,	,	,	,	,	N	O
clomipramine	NN	clomipramine	clomipramine	clomipramin	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.6	CD	7.6	7.6	7.6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
QT	NNP	qt	qt	qt	N	O
Prolonging	NNP	prolonging	prolonging	prolong	N	O
Drugs	NNP	drugs	drug	drug	N	O
and	CC	and	and	and	N	O
Other	JJ	other	other	other	N	O
Antimalarials	NNS	antimalarials	antimalarial	antimalari	N	O

Halofantrine	NNP	halofantrine	halofantrine	halofantrin	N	O
and	CC	and	and	and	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
within	IN	within	within	within	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
each	DT	each	each	each	N	O
other	JJ	other	other	other	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
elimination	NN	elimination	elimination	elimin	N	O
half	NN	half	half	half	N	O
-	:	-	-	-	N	O
life	NN	life	life	life	N	O
of	IN	of	of	of	N	O
lumefantrine	NN	lumefantrine	lumefantrine	lumefantrin	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
potential	JJ	potential	potential	potenti	N	O
additive	JJ	additive	additive	addit	N	O
effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Antimalarials	NNS	antimalarials	antimalarial	antimalari	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
given	VBN	given	given	given	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
,	,	,	,	,	N	O
unless	IN	unless	unless	unless	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
other	JJ	other	other	other	N	O
treatment	NN	treatment	treatment	treatment	N	O
option	NN	option	option	option	N	O
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
limited	JJ	limited	limited	limit	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
.	.	.	.	.	N	O

Drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
antimalarials	NNS	antimalarials	antimalarial	antimalari	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
quinine	NN	quinine	quinine	quinin	N	O
and	CC	and	and	and	N	O
quinidine	NN	quinidine	quinidine	quinidin	N	O
,	,	,	,	,	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
following	VBG	following	following	follow	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
,	,	,	,	,	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
long	JJ	long	long	long	N	O
elimination	NN	elimination	elimination	elimin	N	O
half	NN	half	half	half	N	O
-	:	-	-	-	N	O
life	NN	life	life	life	N	O
of	IN	of	of	of	N	O
lumefantrine	NN	lumefantrine	lumefantrine	lumefantrin	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
6	CD	6	6	6	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
additive	JJ	additive	additive	addit	N	O
effects	NNS	effects	effect	effect	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
;	:	;	;	;	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
advised	VBN	advised	advised	advis	N	O
if	IN	if	if	if	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
prolong	VBP	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
is	VBZ	is	is	is	N	O
medically	RB	medically	medically	medic	N	O
required	JJ	required	required	requir	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.7	CD	7.7	7.7	7.7	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
mefloquine	NN	mefloquine	mefloquine	mefloquin	N	O
is	VBZ	is	is	is	N	O
administered	VBN	administered	administered	administ	N	O
immediately	RB	immediately	immediately	immedi	N	O
prior	JJ	prior	prior	prior	N	O
to	TO	to	to	to	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
there	EX	there	there	there	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
decreased	JJ	decreased	decreased	decreas	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
lumefantrine	VB	lumefantrine	lumefantrine	lumefantrin	N	O
,	,	,	,	,	N	O
possibly	RB	possibly	possibly	possibl	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
mefloquine	NN	mefloquine	mefloquine	mefloquin	N	O
-	:	-	-	-	N	O
induced	JJ	induced	induced	induc	N	O
decrease	NN	decrease	decrease	decreas	N	O
in	IN	in	in	in	N	O
bile	JJ	bile	bile	bile	N	O
production	NN	production	production	product	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
decreased	JJ	decreased	decreased	decreas	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
food	NN	food	food	food	N	O
consumption	NN	consumption	consumption	consumpt	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
encouraged	VBN	encouraged	encouraged	encourag	N	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.4	CD	7.4	7.4	7.4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O
with	IN	with	with	with	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O

When	WRB	when	when	when	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
are	VBP	are	are	are	N	O
coadministered	VBN	coadministered	coadministered	coadminist	N	O
with	IN	with	with	with	N	O
substrates	NNS	substrates	substrate	substrat	N	O
of	IN	of	of	of	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
it	PRP	it	it	it	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
decreased	JJ	decreased	decreased	decreas	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
substrate	NN	substrate	substrate	substrat	N	O
and	CC	and	and	and	N	O
potential	JJ	potential	potential	potenti	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
substrate	JJ	substrate	substrate	substrat	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
are	VBP	are	are	are	N	O
coadministered	VBN	coadministered	coadministered	coadminist	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	O
of	IN	of	of	of	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
grapefruit	NN	grapefruit	grapefruit	grapefruit	N	O
juice	NN	juice	juice	juic	N	O
it	PRP	it	it	it	N	O
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
increased	JJ	increased	increased	increas	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
artemether	NN	artemether	artemether	artemeth	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
lumefantrine	NN	lumefantrine	lumefantrine	lumefantrin	N	O
and	CC	and	and	and	N	O
potentiate	NN	potentiate	potentiate	potenti	N	O
QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
.	.	.	.	.	N	O

When	WRB	when	when	when	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
are	VBP	are	are	are	N	O
coadministered	VBN	coadministered	coadministered	coadminist	N	O
with	IN	with	with	with	N	O
inducers	NNS	inducers	inducer	induc	N	O
of	IN	of	of	of	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
it	PRP	it	it	it	N	O
may	MD	may	may	may	N	O
result	VB	result	result	result	N	O
in	IN	in	in	in	N	O
decreased	JJ	decreased	decreased	decreas	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
artemether	NN	artemether	artemether	artemeth	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
lumefantrine	JJ	lumefantrine	lumefantrine	lumefantrin	N	O
and	CC	and	and	and	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
antimalarial	JJ	antimalarial	antimalarial	antimalari	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
mixed	JJ	mixed	mixed	mix	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
CYP3A4	NNP	cyp3a4	cyp3a4	cyp3a4	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
antiretroviral	JJ	antiretroviral	antiretroviral	antiretrovir	N	O
drugs	NNS	drugs	drug	drug	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
HIV	NNP	hiv	hiv	hiv	N	O
protease	NN	protease	protease	proteas	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
and	CC	and	and	and	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
nucleoside	JJ	nucleoside	nucleoside	nucleosid	N	O
reverse	NN	reverse	reverse	revers	N	O
transcriptase	NN	transcriptase	transcriptase	transcriptas	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
those	DT	those	those	those	N	O
that	WDT	that	that	that	N	O
have	VBP	have	have	have	N	O
an	DT	an	an	an	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNPS	tablets	tablet	tablet	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.3	CD	7.3	7.3	7.3	N	O
,	,	,	,	,	N	O
7.7	CD	7.7	7.7	7.7	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
may	MD	may	may	may	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
effectiveness	NN	effectiveness	effectiveness	effect	N	O
of	IN	of	of	of	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
oral	JJ	oral	oral	oral	N	O
,	,	,	,	,	N	O
transdermal	JJ	transdermal	transdermal	transderm	N	O
patch	NN	patch	patch	patch	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
systemic	JJ	systemic	systemic	system	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
contraceptives	NNS	contraceptives	contraceptive	contracept	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
use	VB	use	use	use	N	O
an	DT	an	an	an	N	O
additional	JJ	additional	additional	addit	N	O
non	NN	non	non	non	N	O
-	:	-	-	-	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
method	NN	method	method	method	N	O
of	IN	of	of	of	N	O
birth	NN	birth	birth	birth	N	O
control	NN	control	control	control	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.5	CD	7.5	7.5	7.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNS	interactions	interaction	interact	N	O
with	IN	with	with	with	N	O
CYP2D6	NNP	cyp2d6	cyp2d6	cyp2d6	N	O

Administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
with	IN	with	with	with	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
are	VBP	are	are	are	N	O
metabolized	VBN	metabolized	metabolized	metabol	N	O
by	IN	by	by	by	N	O
CYP2D6	NNP	cyp2d6	cyp2d6	cyp2d6	N	O
may	MD	may	may	may	N	O
significantly	RB	significantly	significantly	significantli	N	O
increase	VB	increase	increase	increas	N	O
plasma	JJ	plasma	plasma	plasma	N	O
concentrations	NNS	concentrations	concentration	concentr	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
coadministered	JJ	coadministered	coadministered	coadminist	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
effects	NNS	effects	effect	effect	N	O
.	.	.	.	.	N	O

Many	JJ	many	many	mani	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
drugs	NNS	drugs	drug	drug	N	O
metabolized	VBN	metabolized	metabolized	metabol	N	O
by	IN	by	by	by	N	O
CYP2D6	NNP	cyp2d6	cyp2d6	cyp2d6	N	O
can	MD	can	can	can	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNS	tablets	tablet	tablet	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
additive	JJ	additive	additive	addit	N	O
effect	NN	effect	effect	effect	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
flecainide	RB	flecainide	flecainide	flecainid	N	O
,	,	,	,	,	N	O
imipramine	NN	imipramine	imipramine	imipramin	N	O
,	,	,	,	,	N	O
amitriptyline	NN	amitriptyline	amitriptyline	amitriptylin	N	O
,	,	,	,	,	N	O
clomipramine	NN	clomipramine	clomipramine	clomipramin	N	O
)	)	)	)	)	N	O
[	FW	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Drug	NNP	drug	drug	drug	N	O
Interactions	NNP	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.6	CD	7.6	7.6	7.6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Recrudescence	NN	recrudescence	recrudescence	recrudesc	N	O

Food	NNP	food	food	food	N	O
enhances	NNS	enhances	enhances	enhanc	N	O
absorption	NN	absorption	absorption	absorpt	N	O
of	IN	of	of	of	N	O
artemether	NN	artemether	artemether	artemeth	N	O
and	CC	and	and	and	N	O
lumefantrine	NN	lumefantrine	lumefantrine	lumefantrin	N	O
following	VBG	following	following	follow	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
remain	VBP	remain	remain	remain	N	O
averse	JJ	averse	averse	avers	N	O
to	TO	to	to	to	N	O
food	NN	food	food	food	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
closely	RB	closely	closely	close	N	O
monitored	VBN	monitored	monitored	monitor	N	O
as	IN	as	a	as	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
recrudescence	NN	recrudescence	recrudescence	recrudesc	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
greater	JJR	greater	greater	greater	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
recrudescent	NN	recrudescent	recrudescent	recrudesc	N	O
P.	NNP	p.	p.	p.	N	O
falciparum	NN	falciparum	falciparum	falciparum	N	O
infection	NN	infection	infection	infect	Y	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNP	tablets	tablet	tablet	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
different	JJ	different	different	differ	N	O
antimalarial	JJ	antimalarial	antimalarial	antimalari	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	O
and	CC	and	and	and	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O

Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNS	tablets	tablet	tablet	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
for	IN	for	for	for	N	O
efficacy	NN	efficacy	efficacy	efficaci	N	O
and	CC	and	and	and	N	O
safety	NN	safety	safety	safeti	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.4	CD	2.4	2.4	2.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Plasmodium	NNP	plasmodium	plasmodium	plasmodium	N	O
vivax	NN	vivax	vivax	vivax	N	O
Infection	NN	infection	infection	infect	Y	O

Coartem	NNP	coartem	coartem	coartem	N	O
Tablets	NNS	tablets	tablet	tablet	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
limited	JJ	limited	limited	limit	N	O
data	NNS	data	data	data	N	O
(	(	(	(	(	N	O
43	CD	43	43	43	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
effective	JJ	effective	effective	effect	N	O
in	IN	in	in	in	N	O
treating	VBG	treating	treating	treat	N	O
the	DT	the	the	the	N	O
erythrocytic	JJ	erythrocytic	erythrocytic	erythrocyt	N	O
stage	NN	stage	stage	stage	N	O
of	IN	of	of	of	N	O
P.	NNP	p.	p.	p.	N	O
vivax	JJ	vivax	vivax	vivax	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
relapsing	VBG	relapsing	relapsing	relaps	N	O
malaria	NNS	malaria	malaria	malaria	Y	O
caused	VBN	caused	caused	caus	N	O
by	IN	by	by	by	N	O
P.	NNP	p.	p.	p.	N	O
vivax	NN	vivax	vivax	vivax	N	O
requires	VBZ	requires	requires	requir	N	O
additional	JJ	additional	additional	addit	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
antimalarial	JJ	antimalarial	antimalarial	antimalari	N	O
agents	NNS	agents	agent	agent	N	O
to	TO	to	to	to	N	O
achieve	VB	achieve	achieve	achiev	N	O
radical	JJ	radical	radical	radic	N	O
cure	NN	cure	cure	cure	N	O
i	NN	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
eradicate	VBP	eradicate	eradicate	erad	N	O
any	DT	any	any	ani	N	O
hypnozoites	NNS	hypnozoites	hypnozoites	hypnozoit	N	O
forms	NNS	forms	form	form	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
remain	VB	remain	remain	remain	N	O
dormant	JJ	dormant	dormant	dormant	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
liver	NN	liver	liver	liver	N	O
.	.	.	.	.	N	O

